Valneva SE (VALN)
| Market Cap | 478.61M |
| Revenue (ttm) | 201.10M |
| Net Income (ttm) | -86.89M |
| Shares Out | 153.87M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,864 |
| Open | 5.64 |
| Previous Close | 5.75 |
| Day's Range | 5.64 - 5.97 |
| 52-Week Range | 3.62 - 8.66 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 15.33 (+164.31%) |
| Earnings Date | Aug 12, 2025 |
About VALN
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price forecast is $15.33, which is an increase of 164.31% from the latest price.
News
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world's larges...
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors wer...
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above...
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Pha...
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined ...
Valneva to Participate at U.S. and European Investor Conferences in June
Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings ...
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers ...
Valneva SE (VALN) Q1 2025 Earnings Call Transcript
Valneva SE (NASDAQ:VALN) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President-Global Investor Relations Thomas Lingelbach - Chief Executive Offic...
Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance
Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva's main revenue vertical. D...
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Va...
Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people
The European Union's health regulator said on Wednesday it has begun a review of Valneva's chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally.
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, pr...
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité d...
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for...
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, whic...
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
The Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to Valneva SE's VALN single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in ind...
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
Saint Herblain (France), April 14, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted m...
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Saint Herblain (France) and Schlieren (Zurich) , April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech compa...
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm
LOS ANGELES , April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Valneva SE ("Valneva...
Valneva SE Shareholding Declaration - March 2025
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
With this extension, IXCHIQ ® , the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medici...
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus suppl...
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration...
Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly...